190 related articles for article (PubMed ID: 37639602)
21. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice.
Martins IC; Kuperstein I; Wilkinson H; Maes E; Vanbrabant M; Jonckheere W; Van Gelder P; Hartmann D; D'Hooge R; De Strooper B; Schymkowitz J; Rousseau F
EMBO J; 2008 Jan; 27(1):224-33. PubMed ID: 18059472
[TBL] [Abstract][Full Text] [Related]
22. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.
Johannesson M; Sahlin C; Söderberg L; Basun H; Fälting J; Möller C; Zachrisson O; Sunnemark D; Svensson A; Odergren T; Lannfelt L
Mol Cell Neurosci; 2021 Jul; 114():103641. PubMed ID: 34091073
[TBL] [Abstract][Full Text] [Related]
23. Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.
Söllvander S; Ekholm-Pettersson F; Brundin RM; Westman G; Kilander L; Paulie S; Lannfelt L; Sehlin D
J Alzheimers Dis; 2015; 48(1):63-72. PubMed ID: 26401929
[TBL] [Abstract][Full Text] [Related]
24. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
Vitek GE; Decourt B; Sabbagh MN
Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
[TBL] [Abstract][Full Text] [Related]
25. A new class of monoclonal Aβ antibodies selectively targets and triggers deposition of Aβ protofibrils.
Grover S; Pham T; Jones A; Sinobas-Pereira C; Villoch Diaz Maurino M; Garrad EC; Makoni NJ; Parks A; Domalewski RJ; Riggio G; An H; Chen K; Nichols MR
J Neurochem; 2023 Jun; 165(6):860-873. PubMed ID: 37002186
[TBL] [Abstract][Full Text] [Related]
26. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
27. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
28. Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology.
Nichols MR; Moss MA; Reed DK; Cratic-McDaniel S; Hoh JH; Rosenberry TL
J Biol Chem; 2005 Jan; 280(4):2471-80. PubMed ID: 15528204
[TBL] [Abstract][Full Text] [Related]
29. High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain.
Upadhaya AR; Lungrin I; Yamaguchi H; Fändrich M; Thal DR
J Cell Mol Med; 2012 Feb; 16(2):287-95. PubMed ID: 21418518
[TBL] [Abstract][Full Text] [Related]
30. A possible new role for Aβ in vascular and inflammatory dysfunction in Alzheimer's disease.
Zamolodchikov D; Strickland S
Thromb Res; 2016 May; 141 Suppl 2():S59-61. PubMed ID: 27207427
[TBL] [Abstract][Full Text] [Related]
31. Multipronged Regulatory Functions of Serum Albumin in Early Stages of Amyloid-β Aggregation.
Zhao M; Guo C
ACS Chem Neurosci; 2021 Jul; 12(13):2409-2420. PubMed ID: 34160192
[TBL] [Abstract][Full Text] [Related]
32. Biophysical comparison of soluble amyloid-β(1-42) protofibrils, oligomers, and protofilaments.
Nichols MR; Colvin BA; Hood EA; Paranjape GS; Osborn DC; Terrill-Usery SE
Biochemistry; 2015 Apr; 54(13):2193-204. PubMed ID: 25756466
[TBL] [Abstract][Full Text] [Related]
33. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.
Rizoska B; Zachrisson O; Appelkvist P; Boström E; Björklund M; Rachalski A; Gkanatsiou E; Kylefjord H; Söderberg L; Nygren P; Eriksson F; Ishikawa Y; Fukushima T; Koyama A; Osswald G; Lannfelt L; Möller C
Mol Cell Neurosci; 2024 Jun; 130():103950. PubMed ID: 38901655
[TBL] [Abstract][Full Text] [Related]
34. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
[TBL] [Abstract][Full Text] [Related]
35. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
Zhang J
Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
[TBL] [Abstract][Full Text] [Related]
36. A hexameric peptide barrel as building block of amyloid-β protofibrils.
Lendel C; Bjerring M; Dubnovitsky A; Kelly RT; Filippov A; Antzutkin ON; Nielsen NC; Härd T
Angew Chem Int Ed Engl; 2014 Nov; 53(47):12756-60. PubMed ID: 25256598
[TBL] [Abstract][Full Text] [Related]
37. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
Lambert MP; Viola KL; Chromy BA; Chang L; Morgan TE; Yu J; Venton DL; Krafft GA; Finch CE; Klein WL
J Neurochem; 2001 Nov; 79(3):595-605. PubMed ID: 11701763
[TBL] [Abstract][Full Text] [Related]
39. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
40. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein.
Harper JD; Lieber CM; Lansbury PT
Chem Biol; 1997 Dec; 4(12):951-9. PubMed ID: 9427660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
